assignment
Recruiting

Phase I/II Evaluation of Sodium 2-HYDROXYLINOLEATE, Irinotecan, and Temozolomide in Pediatric Relapsed/Refractory Neuroblastoma and Solid Tumors

Trial ID
2023-504246-64-02
Protocol
ETNA

Register record, history and transparency: CTIS.eu

Trial statistics

science
3
test molecules
location_city
6
research sites
public
1
country
medical_information
2
diseases
person_search
9
investigators

Diseases & Conditions

NeuroblastomaNeoplasm

Objectives

The primary objective of this phase I/II trial is to define the **paediatric recommended phase 2 dose (RP2D)** of ABTL0812, both as a single agent and in combination with chemotherapy (irinotecan-temozolomide) or targeted therapies, in children with relapsed/refractory neuroblastoma and other solid tumors. Establishing the RP2D is crucial for optimizing therapeutic efficacy while minimizing adverse effects, thereby enhancing treatment outcomes in this pediatric population.

Secondary objectives include evaluating the safety profile, antitumor activity, progression-free survival, overall survival, pharmacokinetics, and pharmacodynamics of ABTL0812 in children. These assessments are essential for understanding the broader clinical impact of ABTL0812 and its potential role in pediatric oncology treatment regimens.

Participants

The clinical trial involves participants diagnosed with **relapsed/refractory neuroblastoma and other solid tumors**. The study population includes both male and female subjects aged between 1 and 21 years. Participants are required to have a body surface area of at least 0.5 m² and must be capable of swallowing intact capsules. The trial does not involve a vulnerable population. Participants must have a solid tumor that has progressed, relapsed, or is refractory to at least one standard therapy, with no known curative options available. Adequate performance status and sufficient hematological, hepatic, and renal function are necessary for inclusion. The sponsor has not provided information regarding the total number of participants. Lifestyle considerations such as diet and physical activity are not specified. Key inclusion criteria include the ability to provide informed consent and, for women of childbearing age, a negative pregnancy test and the use of appropriate contraceptive methods. The trial aims to define the pediatric recommended phase 2 dose of ABTL0812, both as a single agent and in combination with chemotherapy or targeted therapies.

Plans and Procedures

The clinical trial is designed as a **phase I/II** study to evaluate the safety and efficacy of **ABTL0812** in pediatric patients with relapsed or refractory **neuroblastoma** and other solid tumors. The trial employs a **randomized, double-blind, controlled** methodology to ensure unbiased results. The primary objective is to define the recommended phase 2 dose (RP2D) of ABTL0812, both as a single agent and in combination with chemotherapy agents **irinotecan** and **temozolomide**. The trial is expected to commence recruitment on December 2, 2024, and conclude by December 29, 2028.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on criteria such as age, ability to swallow capsules, and adequate organ function. Following successful screening, participants will be enrolled and randomized into treatment cohorts. The study includes multiple follow-up visits to monitor safety, efficacy, and any dose-limiting toxicities, particularly during the first cycle of treatment. The end-of-study visit will evaluate the overall outcomes and any long-term effects of the treatment.

The expected duration of participant involvement varies depending on individual response and tolerance to the treatment, but it generally spans the entire trial period. Conditions that may lead to early termination from the study include significant adverse reactions, disease progression, or withdrawal of consent. The trial is structured to ensure rigorous monitoring and adherence to ethical standards, with informed consent obtained from all participants or their legal guardians prior to any study-specific procedures.

Treatment

The clinical trial involves the administration of **ABTL0812**, an experimental medication formulated as a **capsule**. The active substance in ABTL0812 is **sodium 2-hydroxylinoleate**, a chemical compound. This medication is administered **orally** and is specifically designed for pediatric use. ABTL0812 is classified as an **oncological** agent and has been designated as an orphan drug under the designation number EU/3/15/1485. The primary objective of the trial is to determine the recommended phase 2 dose (RP2D) of ABTL0812 when used as a single agent and in combination with other therapies.

In addition to ABTL0812, the trial includes the use of **TEMOZOLOMIDE**, a cytostatic agent. TEMOZOLOMIDE is provided in the form of a **hard capsule** and is also administered **orally**. The active substance, **temozolomide**, is a chemical compound. TEMOZOLOMIDE is not specifically formulated for pediatric use and does not have orphan drug status in this trial. It serves as an auxiliary treatment in combination with ABTL0812.

Another auxiliary treatment in the trial is **IRINOTECAN**, an antineoplastic agent. IRINOTECAN is administered as a **solution for injection** via **intravenous perfusion**. The active substance, **irinotecan**, is a chemical compound. Similar to TEMOZOLOMIDE, IRINOTECAN is not formulated for pediatric use and does not have orphan drug status in this trial. The combination of IRINOTECAN and TEMOZOLOMIDE with ABTL0812 aims to explore potential synergistic effects in treating relapsed or refractory neuroblastoma and other solid tumors in children.

Efficacy

The efficacy of the clinical trial involving ABTL0812 in children with relapsed or refractory neuroblastoma and other solid tumors will be assessed primarily through the **incidence of dose-limiting toxicities**. This parameter will be evaluated during the first cycle of study treatment for cohorts A and B. The trial aims to define the pediatric recommended phase 2 dose (RP2D) of ABTL0812, both as a single agent and in combination with chemotherapy agents such as irinotecan and temozolomide, or targeted therapies. The assessment of dose-limiting toxicities will provide critical data on the safety and tolerability of the treatment regimen, which is essential for determining the appropriate dosing for subsequent phases of the trial.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Signed informed consent of the patient, parents or legal representatives before any study-specific screening procedures are conducted, and age-appropriate assent. 2. Aged 1 to ≤21 years at time of signing informed consent. 3. BSA ≥0.5 m2 . 4. Patient must be able to swallow intact capsules. 5. Diagnosis of a solid tumour that has progressed, relapsed or is refractory to at least one standard therapy and/or for which there is not known curative option. Histologic confirmation of progression or relapse is recommended but not mandatory. 6. At least one evaluable or measurable radiological site of disease as defined by INRC, RECIST v1.1 or RAPNO criteria. 7. Adequate performance status: Patients 60%. Patients ≥16 years of age: Karnofsky >60%. 8. Adequate haematological, hepatic and renal function defined by the following laboratory results obtained within 7 days prior to initiation of study drug according to CTCAE v5.0: *Haematological function: - Haemoglobin ≥ 8 g/dL (transfusion allowed). - Peripheral ANC ≥1x109 /L. No G-CSF support for 72 hours prior to initiation of study treatment. Pegylated forms need a wash-out of 7 days. - Platelet count ≥75x109 /L, unsupported for 72 hours prior to initiation of study treatment. *Renal and liver function: - Normal serum creatinine based on age/gender. If serum creatinine is greater than maximum serum creatinine for age/gender, then creatinine clearance (or radioisotope glomerular filtration rate [GFR]) must be >70 mL/min/1.73m2 . - Total bilirubin ≤1.5 x ULN (≤3 x ULN if liver metastases). - AST or ALT ≤3 x ULN (≤5 x ULN if liver metastases). 9. Appropriate contraceptive methods for sexually active males and women of childbearing age. 10. A negative pregnancy test for women of childbearing age. 11. Absence of any psychological, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up Schedule
cancel

Exclusion Criteria

  • Symptomatic or bleeding CNS metastases that result in a neurologically unstable clinical state or require increasing doses of corticosteroids or local CNS-directed therapy to control. 2. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that in the opinion of the investigator might affect the absorption of ABTL0812 or temozolomide. 3. Any additional uncontrolled illness or known active infection, including HBV, HCV and HIV. 4. Presence of any grade >2 clinically significant toxicities related to prior treatments with the exception of alopecia, peripheral neuropathy or other long-term sequelae of cancer therapy, and parameters otherwise permitted in the inclusion criteria. 5. Any uncontrolled medical condition or other identified abnormality that precludes the patient's safe participation in and completion of the study, as judged by the investigator. 6. Systemic anticancer therapy within 21 days or 5 half-lives, whichever is shorter, prior to initiation of study treatment. Seven days for oral metronomic chemotherapy. 7. I-131 MIBG therapy within 6 weeks prior to initiation of study treatment. 8. Myeloablative therapy with autologous hematopoietic stem cell rescue within 60 days or allogeneic hematopoietic stem cell rescue within 120 days of study treatment initiation. 9. Active graft versus host disease requiring systemic therapy. 10. Radiotherapy (non-palliative) within 21 days prior to study treatment initiation. 11. Major surgical procedure within 21 days of study treatment initiation, or anticipated need for major surgical procedure during the course of the study

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Spain SpainRecruiting02 Dec 202448

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
ABTL0812
TestCAPSULEORAL——PRD10568698
IRINOTECAN
Other—INTRAVENOUS PERFUSION USE——SUB08295MIG
TEMOZOLOMIDE
Other—ORAL——SUB10889MIG

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Irinotecan
62 trials

Also investigated for

Colorectal cancer metastatic 18Pancreatic carcinoma metastatic 7Colorectal cancer 6Adenocarcinoma pancreas 5
vaccines
Temozolomide
59 trials

Also investigated for

Glioblastoma 18Neuroblastoma 7Glioma 5Neoplasm 5
vaccines
Sodium 2-HYDROXYLINOLEATE
3 trials

Also investigated for

Neuroblastoma 2Neoplasm 1Pancreatic carcinoma metastatic 1